ALX Oncology reported a net loss of $57.7 million for the nine months ended September 30, 2026, an improvement from the $78.8 million loss in the prior year period. The company significantly strengthened its balance sheet through equity offerings, increasing total stockholders' equity to $125.9 million from $26.0 million at the end of 2025.
ALX Oncology reported third quarter 2026 financial results, ending the period with $147.2 million in cash and investments, which is expected to fund operations through the first half of 2028. The company highlighted clinical progress for evorpacept and ALX2004, with topline data from the ASPEN-09-Breast trial now expected in the second half of 2027.
“Throughout the third quarter, we continued to make significant progress across both the ASPEN-09-Breast and ALX2004 clinical trials. The recent publication of ASPEN-06 results in Nature Medicine further reinforces the promise of evorpacept and our biomarker-driven development strategy.”
Jason Lettmann, Chief Executive Officer of ALX Oncology
ALX Oncology entered into exchange agreements with certain stockholders, including funds affiliated with Blackstone, RA Capital, and venBio, to exchange 13,353,384 shares of common stock for an equivalent number of pre-funded warrants. This transaction is a non-cash exchange of equity classes intended to manage beneficial ownership levels, as the warrants include exercise limitations to prevent holders from exceeding specific ownership thresholds.